These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 10500211)

  • 1. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
    Scholler N; Fu N; Yang Y; Ye Z; Goodman GE; Hellström KE; Hellström I
    Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11531-6. PubMed ID: 10500211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesothelin variant 1 is released from tumor cells as a diagnostic marker.
    Hellstrom I; Raycraft J; Kanan S; Sardesai NY; Verch T; Yang Y; Hellstrom KE
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):1014-20. PubMed ID: 16702385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
    Hassan R; Remaley AT; Sampson ML; Zhang J; Cox DD; Pingpank J; Alexander R; Willingham M; Pastan I; Onda M
    Clin Cancer Res; 2006 Jan; 12(2):447-53. PubMed ID: 16428485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma.
    Inami K; Kajino K; Abe M; Hagiwara Y; Maeda M; Suyama M; Watanabe S; Hino O
    Oncol Rep; 2008 Dec; 20(6):1375-80. PubMed ID: 19020717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
    Onda M; Nagata S; Ho M; Bera TK; Hassan R; Alexander RH; Pastan I
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4225-31. PubMed ID: 16857795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
    J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients.
    Hellstrom I; Friedman E; Verch T; Yang Y; Korach J; Jaffar J; Swisher E; Zhang B; Ben-Baruch G; Tan MC; Goedegebuure P; Hellstrom KE
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1520-6. PubMed ID: 18559570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesothelin: a new target for immunotherapy.
    Hassan R; Bera T; Pastan I
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3937-42. PubMed ID: 15217923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats.
    Sathyanarayana BK; Hahn Y; Patankar MS; Pastan I; Lee B
    BMC Struct Biol; 2009 Jan; 9():1. PubMed ID: 19128473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.
    Shiomi K; Miyamoto H; Segawa T; Hagiwara Y; Ota A; Maeda M; Takahashi K; Masuda K; Sakao Y; Hino O
    Cancer Sci; 2006 Sep; 97(9):928-32. PubMed ID: 16776777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor.
    Huang CY; Cheng WF; Lee CN; Su YN; Chien SC; Tzeng YL; Hsieh CY; Chen CA
    Anticancer Res; 2006; 26(6C):4721-8. PubMed ID: 17214332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
    Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
    Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization, molecular cloning and expression of megakaryocyte potentiating factor.
    Yamaguchi N; Yamamura Y; Konishi E; Ueda K; Kojima T; Hattori K; Oheda M; Imai N; Taniguchi Y; Tamura M; Ochi N
    Stem Cells; 1996; 14 Suppl 1():62-74. PubMed ID: 11012204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
    Anderson GL; McIntosh M; Wu L; Barnett M; Goodman G; Thorpe JD; Bergan L; Thornquist MD; Scholler N; Kim N; O'Briant K; Drescher C; Urban N
    J Natl Cancer Inst; 2010 Jan; 102(1):26-38. PubMed ID: 20042715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
    Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
    Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
    Chang K; Pastan I
    Proc Natl Acad Sci U S A; 1996 Jan; 93(1):136-40. PubMed ID: 8552591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
    Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
    Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
    Ho M; Hassan R; Zhang J; Wang QC; Onda M; Bera T; Pastan I
    Clin Cancer Res; 2005 May; 11(10):3814-20. PubMed ID: 15897581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
    Creaney J; Sneddon S; Dick IM; Dare H; Boudville N; Musk AW; Skates SJ; Robinson BW
    Dis Markers; 2013; 35(2):119-27. PubMed ID: 24167356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.